| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 1.9MM | +5% |
| Gross Profit | 374K | -4% |
| Cost Of Revenue | 1.5MM | +7% |
| Operating Income | -4.6MM | +14% |
| Operating Expenses | 5MM | +13% |
| Net Income | -5MM | +12% |
| R&D | 1.2MM | +10% |
| G&A | 3.8MM | +14% |
| Interest Expense | 427K | -6% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Avinger (AVGR) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Avinger (AVGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is how Edwards Lifesciences (EW) and Avinger (AVGR) have performed compared to their sector so far this year.
Avinger, Inc. (NASDAQ:AVGR) Q4 2023 Earnings Call Transcript March 20, 2024 Avinger, Inc. misses on earnings expectations. Reported EPS is $-3.93 EPS, expectations were $0.64. AVGR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to Avinger’s Fourth Quarter […]
New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens New Pathway for Sales in Asia REDWOOD CITY, CA / ACCESSWIRE / March 20, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical ...
REDWOOD CITY, CA / ACCESSWIRE / March 12, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, ...
Initial $7.5 Million Strategic Investment Strategic Partnership Opens Pathway to Access Greater China Market Strengthened Balance Sheet and Three-Year Extension of Existing Debt Terms REDWOOD CITY, CA / ACCESSWIRE / March 6, 2024 / Avinger, Inc. (Nasdaq:AVGR), ...
Avinger, Inc. (NASDAQ:AVGR) Q3 2023 Earnings Call Transcript October 26, 2023 Avinger, Inc. misses on earnings expectations. Reported EPS is $-2.92 EPS, expectations were $-2.85. Operator: Greetings. Welcome to the Avinger Third Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. […]
Avinger (AVGR) delivered earnings and revenue surprises of -2.46% and 24.29%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, CA / ACCESSWIRE / October 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of ...